Immunoassay Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Kits, and Consumables & Accessories), By Detection Technology (Chemiluminescence & Electrochemiluminescence, Colorimetric, Fluorescence, and Radioimmunoassays), By Application (Clinical Diagnostics [Infectious Diseases, Endocrinology, Cardiac Disorders, and Oncology] and Non-Clinical Applications [Drug Discovery]), By End-User (Hospitals & Clinics, Independent & Reference Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes), and Regional Forecast, 2026-2034

The global immunoassay market size was valued at USD 26.80 billion in 2025. The market is projected to grow from USD 28.81 billion in 2026 to USD 51.80 billion by 2034, exhibiting a CAGR of 7.6% during the forecast period. North America dominated the immunoassay market with a market share of 33.76% in 2025.

Immunoassay includes instruments, reagents & kits, and other related consumables and accessories for detecting and quantifying antibodies, hormones, antigens, proteins, drugs, and disease-associated biomarkers. They are routinely employed in infectious disease testing, endocrinology, cardiology, oncology, autoimmune and allergy testing, neurology, reproductive health, drug development, and academic research. The global market growth is driven by increasing prevalence of chronic diseases and increasing diagnostic volumes across the globe.

Furthermore, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Abbott, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. held the highest market share in 2025 due to their strong brand reputation.

Download Free sample to learn more about this report.

IMMUNOASSAY MARKET TRENDS

Increasing Integration of Automation and Artificial Intelligence in Immunoassay Platforms to Emerge as a Key Trend

The integration of automation and Artificial Intelligence (AI) is emerging as a significant trend in the market, particularly across high-throughput clinical laboratories and diagnostic centers. Automated immunoassay analyzers streamline several testing stages, including sample handling, reagent dispensing, incubation, detection, and result interpretation, thereby reducing manual intervention and improving laboratory productivity.

AI-enabled software is further enhancing these systems by supporting automated quality control, pattern recognition, predictive maintenance, and interpretation of complex assay results. These capabilities help laboratories minimize operational errors, improve turnaround times, and manage increasing diagnostic workloads with limited technical staff. In addition, advanced algorithms are being incorporated into digital immunoassay and multiplex testing platforms to improve analytical sensitivity and support more accurate biomarker quantification.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Adoption of Biomarker-Based Diagnosis and Disease Monitoring to Fuel the Market Expansion

In recent years, there has been an increasing disease burden and dependence on biomarker-based diagnosis, which is driving demand for immunoassay test volumes across hospitals, reference laboratories, and outpatient facilities. They support rapid and repeat testing for infections, thyroid disorders, cardiac injury, cancer markers, fertility conditions, autoimmune diseases, and neurological disorders.

Moreover, as the role of immunoassay is growing, healthcare systems are moving toward earlier diagnosis and longitudinal monitoring rather than symptom-based intervention. This is also leading to increased product approvals to meet the growing demand, thereby contributing to the immunoassay market growth.

• For instance, in October 2025, Hoffmann-La Roche Ltd received CE Mark for its automated Elecsys Dengue Ag immunoassay, which provides results in approximately 18 minutes.

MARKET RESTRAINTS

High Instrument, Reagent, and Lifecycle Costs to Hamper the Market Growth

Although the demand for immunoassay has been increasing, its capital and operating costs is expected to restrict adoption among small laboratories and healthcare facilities in lower-resource markets. Automated systems require investments in instruments, proprietary reagents, calibrators, controls, maintenance contracts, software, trained personnel, and reliable healthcare infrastructure.

Moreover, regulatory compliance further increases development costs, as manufacturers must establish analytical performance, clinical validity, manufacturing consistency, and post-market quality. This is anticipated to limit the market expansion over the forecast period.

MARKET OPPORTUNITIES

Expanding Clinical Utility of Blood-Based Neurological Biomarkers to Offer Lucrative Growth Opportunities

Conditions such as Alzheimer’s disease, traumatic brain injury, multiple sclerosis, and other neurological conditions have traditionally relied on imaging, cerebrospinal fluid analysis, and specialist evaluation for diagnosis and disease monitoring over the past few years. However, these approaches can be invasive, resource-intensive, and dependent on specialized infrastructure, which may limit accessibility and routine clinical use.

In such a scenario, the high-sensitivity automated immunoassays could enable selected neurological biomarkers to be measured in routine laboratories, supporting earlier triage, disease monitoring, and patient referral. This shift is influencing product development and regulatory approvals, creating lucrative opportunities for market expansion. For instance, in April 2026, F. Hoffmann-La Roche Ltd. received CE Mark for its Elecsys NfL blood test for neuroinflammation monitoring in multiple sclerosis.

MARKET CHALLENGES

Assay Interference, Standardization, and Result Comparability to Challenge Market Expansion

Maintaining clinically reliable and comparable results across assays, instruments, laboratories, and patient populations remains a key challenge. Immunoassay products may be affected by cross-reactivity, matrix effects, calibration differences, heterophile antibodies, and interference from substances such as biotin.

As a result, regulatory bodies such as the FDA have issued specific guidance that recommends manufacturers evaluate biotin interference during the development of in-vitro diagnostic devices. Moreover, laboratories must conduct quality control, proficiency testing, verification, and method-comparison studies before introducing new assays. Furthermore, standardized reference systems are unavailable for many analytes, which is expected to slow down the adoption, challenging market expansion.

Segmentation Analysis

By Product Type

Repetitive Consumption of Reagents & Kits to Boost the Segment’s Dominance

Based on product type, the market is segmented into instrument, reagents & kits, and consumables & accessories.

The reagents & kits segment accounted for the largest global immunoassay market share in 2025. Immunoassay testing generates recurring assay-specific consumption as each test requires reagents, substrates, cartridges, conjugates, coated reaction vessels, or complete assay kits. This is anticipated to drive the segment’s growth during the forecast period.

Additionally, the instrument segment is projected to grow at a CAGR of 7.4% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Detection Technology

High Analytical Sensitivity and Large Sample Processing Sustained Chemiluminescence & Electrochemiluminescence Immunoassays’ Leadership

By detection technology, the market is classified into chemiluminescence & electrochemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassays, immunoturbidimetric & nephelometric immunoassays, and others.

The chemiluminescence & electrochemiluminescence immunoassays segment accounted for the largest market share in 2025. The growth is attributed to its high analytical sensitivity, broad measurement range, short turnaround time, and compatibility with fully automated random-access analyzers. These platforms can process large sample volumes and simultaneously support infectious disease, cardiac, oncology, endocrine, reproductive-health, autoimmune, and neurological assays. Moreover, the segment is projected to hold a 43.3% share in 2026.

• For instance, in May 2025, Revvity stated that the IDS i20 could consolidate 20 analytes across six diagnostic specialties and process up to 140 tests per hour.

Additionally, the colorimetric immunoassays segment is expected to grow at a CAGR of 6.2% during the forecast period.

By Application

Extensive Usage of Immunoassays in Clinical Diagnosis Drives the Segment’s Governance

By application, the market is segmented into clinical diagnostics and non-clinical applications. The clinical diagnostics segment is further subdivided into infectious diseases, endocrinology & metabolic disorders, cardiac & vascular disorders, oncology, autoimmune diseases & allergy, neurology, reproductive health & pregnancy, and others. On the other hand, non-clinical applications are sub-segmented into drug discovery & development and academic & translational research.

The clinical diagnostics segment accounted for the largest market share in 2025. Immunoassays are extensively used for routine diagnosis, screening, emergency assessment, and chronic-disease monitoring. Moreover, large testing volumes arise from infectious diseases, thyroid and metabolic disorders, cardiac conditions, cancer biomarkers, autoimmune diseases, allergy, fertility, pregnancy, and neurological disorders, which is anticipated to fuel the segment’s growth. Moreover, the segment is estimated to hold an 87.8% share in 2026.

Additionally, the non-clinical applications segment is anticipated to grow at a rate of 8.9% over the forecast period.

By End-user

Substantial Immunoassay Testing Volumes in Hospitals & Clinics Boosted Segment’s Growth

On the basis of end-user, the market is segmented into hospitals & clinics, independent & reference laboratories, pharmaceutical & biotechnology companies, academic & research institutes, home healthcare, and others.

In 2025, hospitals & clinics dominated the market in end-users as these facilities conduct substantial volumes of routine, emergency, inpatient, and outpatient immunoassay testing. Furthermore, the segment is set to hold a 62.3% share in 2026.

In addition, the independent & reference laboratories segment is projected to grow at a CAGR of 8.0% during the forecast period.

Immunoassay Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America accounted for the largest share of revenues in 2024, valued at USD 8.53 billion, and is projected to grow to USD 9.05 billion by 2025. The growth is supported by advanced clinical laboratory infrastructure, high adoption of automated chemiluminescence and electrochemiluminescence platforms, favorable reimbursement, and frequent testing for various diseases.

• For instance, in July 2026, Laboratory of Florida LLC, there were over 200,000 clinical laboratories across the U.S.

U.S. Immunoassay Market

In 2026, the market in U.S. is anticipated to reach USD 8.89 billion, accounting for approximately 30.9% of the global market.

Europe

Europe is projected to record a 6.6% growth rate during the forecast period, the third-highest globally, reaching USD 7.56 billion by 2026. Countries such as the U.K., Germany, France, Italy, and Spain have significant number of installed bases of automated immunoassay analysers and presence of regional initiatives to strengthen diagnostic standardization. For instance, in March 2024, the European Commission designated the first six European Union Reference Laboratories for public health, followed by three additional reference laboratories in December 2024.

U.K. Immunoassay Market

The market in U.K. is projected to reach USD 1.16 billion by 2026, representing approximately 4.0% of global revenues.

Germany Immunoassay Market

The market in Germany is expected to reach around USD 1.63 billion by 2026, accounting for approximately 5.7% of global revenues.

Asia Pacific

In 2026, the Asia Pacific market is projected to reach approximately USD 9.74 billion, making it the second-largest market. The region’s growth is driven by increasing incidence of infectious and chronic diseases and a growing geriatric population contributing to increased need for clinical diagnosis.

Japan Immunoassay Market

The market in Japan is projected to generate approximately USD 2.30 billion in revenue by 2026, representing nearly 8.0% of the global market.

China Immunoassay Market

The market in China is anticipated to reach around USD 4.77 billion by 2026, accounting for nearly 16.6% of global revenues.

India Immunoassay Market

The market in India is expected to reach approximately USD 0.92 billion by 2026, accounting for around 3.2% of global market revenue.

Latin America and Middle East & Africa

Both Latin America and the Middle East & Africa are anticipated to witness moderate growth, with the Latin America market estimated to reach approximately USD 0.94 billion by 2026. The growth of the Latin America region is attributed to increasing healthcare spending and the focus of prominent players to expand in the untapped areas of these regions. On the other hand, the Middle East & Africa growth is driven by increasing health-screening awareness and improving diagnostic infrastructure.

GCC Immunoassay Market

By 2026, the market in GCC is estimated to reach approximately USD 0.42 billion, representing around 1.5% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Vital Strategic Initiatives and Broad Portfolios to Strengthen the Market Position of Key Players

In 2025, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Abbott, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. held the largest global immunoassay market share due to their broad immunoassay portfolio and strong brand reputation globally. Moreover, other major players are focusing on key initiatives such as acquisitions, partnerships, collaborations, extending R&D investments, new facility launches, and new product launches to strengthen their market footprint globally in the forthcoming years.

LIST OF KEY IMMUNOASSAY COMPANIES PROFILED

• Hoffmann-La Roche Ltd. (Switzerland)
• Abbott (U.S.)
• Siemens Healthineers AG (Germany)
• Beckman Coulter, Inc. (U.S.)
• BIOMÉRIEUX (France)
• QuidelOrtho Corporation (U.S.)
• DiaSorin S.p.A. (Italy)
• Revvity (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• May 2026: Hoffmann-La Roche Ltd. received CE Mark for Elecsys pTau217, a blood-based immunoassay intended to rule in or rule out Alzheimer’s amyloid pathology.
• April 2026: Beckman Coulter, Inc. received CE Mark under IVDR for the Access MeMed BV immunoassay that differentiates bacterial from viral infections.
• March 2026: Siemens Healthineers AG launched automated Atellica IM pTau217 and brain-derived tau assays for neurological and Alzheimer’s disease research.
• January 2026: Fujirebio launched the Lumipulse G pTau217 CSF automated chemiluminescent enzyme immunoassay for research use.
• September 2025: DiaSorin S.p.A. launched the CE-marked LIAISON TSH-R Ab immunoassay to support diagnosis and monitoring of Graves’ disease.
• May 2025: Revvity launched the IDS i20 fully automated random-access chemiluminescence immunoassay platform for specialty testing.
• March 2025: Beckman Coulter, Inc. received FDA 510(k) clearance for the DxC 500i integrated clinical chemistry and immunoassay analyzer.

REPORT COVERAGE

The report provides detailed analysis of all market segments, highlighting the key growth drivers, opportunities, trends, restraints, and challenges shaping the market. It further includes technological advancements, new product launches, approvals, incidence of key diseases, key industry developments, company market share analysis, and profiles of major market players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation